Burning Rock Biotech (BNR) Earnings Forecast
What Wall Street expects this business to earn, and how much analysts disagree.
10 figures withheld by our checks. Each blank figure names its reason.
Are estimates going up or down lately?
Our record of this company's consensus starts with tonight's snapshot. A revision needs two of our own nightly snapshots of one fiscal period to compare, and nothing before the first is reconstructed, because a backfilled revision is a number we never observed.
Measured between two of our own nightly snapshots of one fiscal period, so a new fiscal year entering the view is never read as a revision. Never backfilled. A window still filling says how many days it holds; a blank one means our record is not that long yet.
What you pay for the growth
We hold no forward multiple for Burning Rock Biotech today, so there is nothing here to set against the growth the Street expects.
Is next quarter a high bar or an easy one?
Analysts expect Burning Rock Biotech to lose $2.31 a share in the December quarter, the one estimate published. We hold no expected date for the next report.
For the March quarter, analysts expect a loss of $2.50 a share.
Does Burning Rock Biotech usually beat or miss?
We have not been able to check a quarter yet. We hold no estimate for Burning Rock Biotech yet, so this record starts on the night we first do.
Checked against the company's reported figure (GAAP) and the average estimate we recorded the night before its results release. Where analysts' number is on an adjusted basis, we leave the comparison out rather than force it. A quarter we did not hold an estimate for is never filled in after the fact.
Analysts' price forecasts and grades are not licensed here. This page shows forward consensus estimates only: no near-year analyst count published. Not investment advice.

